L. E. Shepherd

Competing Causes of Death From a Randomized Trial of Extended Adjuvant Endocrine Therapy for Breast Cancer

J-AW Chapman, D. Meng, L. E. Shepherd et al. · JNCI Journal of the National Cancer Institute · 2008 · 182 citations · Full text

Medicine, Oncology, Cancer Epidemiology +14

Gemcitabine, dexamethasone and cisplatin is an active andnon-toxic chemotherapy regimen in relapsed or refractory Hodgkin’s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group

Tara Baetz, Andrew R. Belch, Stephen Couban et al. · Annals of Oncology · 2003 · 160 citations · Full text

Medicine, Oncology, Pharmacology +17

Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole

Paul E. Goss, J. N. Ingle, Silvana Martino et al. · Annals of Oncology · 2012 · 93 citations · Full text

Medicine, Oncology, Breast Oncology +12

Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer

Paul E. Goss, J. N. Ingle, Silvana Martino et al. · Journal of Clinical Oncology · 2004 · 82 citations

Pharmacy, Oncology, Pharmacotherapy +17

Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17

J. N. Ingle, Dongsheng Tu, Joseph L. Pater et al. · Annals of Oncology · 2008 · 65 citations

Medicine, Oncology, Pharmacology +15